Top 8 US vaccine stocks of 2021

Be the First to Comment Read

Top 8 US vaccine stocks of 2021

 Top 8 US vaccine stocks of 2021
Image source: Treecha,Shutterstock

Highlights

  • Pfizer, Inc. (NYSE: PFE) got emergency use authorization for a booster dose from the FDA for Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) on people 16 years and older, on December 9.
  • Moderna, Inc. (NASDAQ: MRNA) delivered around 287 million COVID-19 vaccine doses to the US in the nine months ended September 30.
  • Novavax, Inc. (NASDAQ: NVAX) submitted on November 24, to the Singapore HSA for the interim authorization of its coronavirus vaccine under the Pandemic Special Access Route (PSAR).

The seven-day average for new COVID-19 cases in the US is about 119,000 per day, as per Johns Hopkins University data. The cases reached a low of 71,000 in late October. 

Just when the healthcare industry was hoping for a break, the new Omicron virus came to keep everybody on their toes again. Healthcare and particularly COVID-19 related stocks were impacted. The big questions. Will the vaccine be able to fight the new variant? How deadly is the variant?

Since early November, there has been a surge in Covid-19 hospital admissions, showed Federal data. Amid this uncertainty, the healthcare industry is working hard to lessen the impact of the latest variant. Vaccine maker companies may benefit amid this latest development.

Here we discuss eight healthcare stocks.

Also Read: Five metaverse cryptos that are making news

Pfizer, Inc. (NYSE: PFE)

New York-based Pfizer is engaged in discovering, developing, manufacturing, marketing, selling, and distributing biopharmaceutical products globally. On December 9, the company’s emergency use authorization from the FDA was expanded for a booster dose of Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) on people 16 years and older. The booster dose must be administered after six months of completion of primary doses.  

For the nine months ended October 3, 2021, its revenue was US$57.6 billion compared to US$30.2 billion in the same period in 2020. The net income was US$18.6 billion versus US$8.3 billion in the corresponding nine months of the previous year. 

The company has a market capitalization of US$296 billion. Its P/E ratio is 15.71, and forward P/E ratio for one year is 12.42. Its dividend yield is 3.04%. The stock closed at US$52.78 on December 10. 

Also Read: Seven hot dividend stocks to watch in 2022

Also Read: Intensity Therapeutics (INTS) IPO: How to buy the stock?

BioNTech SE American Depositary Share (NASDAQ: BNTX)

Mainz, Germany-based BioNTech is focused on developing therapeutics for cancer and individualized immunotherapy. It also develops vaccines for infectious diseases, and the COVID-19 vaccine is one it developed together with Pfizer.

On December 6, Pfizer and BioNTech data from preliminary laboratory studies showed that the three shots of the Pfizer-BioNTech Vaccine neutralize the new variant.

For the nine months ended September 30, 2021, the company earned revenue of €13.44 billion compared to €136.9 million in the comparable period in 2020. Its net income was €7.13 billion compared to a net loss of €352 million in the nine months in the previous year.

As of November 2, the company delivered more than 2 billion COVID-19 doses. Its current market capitalization is US$62.5 billion. Its P/E ratio is 7.43, and forward P/E for one year is 6.52. The stock closed at US$257.68 on December 10. 

Also Read: Top metal and mining stocks to explore in 2022

Moderna, Inc. (NASDAQ: MRNA)

Cambridge, Massachusetts-based Moderna is a commercial-stage biotech company. Its mRNA technology has been used in the COVID-19 vaccine, which was authorized in December 2020 in the US.

The company delivered around 287 million COVID-19 vaccine doses to the U.S. Government and approximately 222 million doses to other governments in the nine months ended September 30, 2021.

On December 10, the company announced accelerating the supply of 20 million doses to COVAX by December 31, 2021, under an amendment of the contract with vaccine alliance Gavi. 

For the nine months ended September 30, 2021, the revenue of the company was US$11.2 billion compared to US$232 million in the same period the previous year. The net income for the period was US$7.33 billion against a net loss of US$474 million in the corresponding period in 2020.

The company has a market capitalization of US$104 billion. Its P/E ratio is 15.76, and forward P/E for one year is 9.64. The stock closed at US$257.06 on December 10. 

Also Read: Top consumer stocks that shined in 2021

Novavax, Inc. (NASDAQ: NVAX)

Gaithersburg, Maryland-based Novavax is a clinical-stage biotechnology company engaged in developing vaccines. 

On November 24, the company submitted to the Singapore Health Sciences Authority (HSA) for the interim authorization of its COVID-19 vaccine under the Pandemic Special Access Route (PSAR).

The company posted revenue of US$924 million for the nine months ended September 30, 2021, versus revenue of US$195 million for the corresponding period in 2020. The net loss per share diluted was US$12.13 in the nine months of 2021 against US$4.39 net loss per share diluted in the previous year’s period.

The company has a market capitalization of US$12.6 billion. Its stock closed at US$166.56 on December 10. 

Also Read: Red hot blue-chip technology stocks to explore in 2022

Vir Biotechnology, Inc. (NASDAQ: VIR)

San Francisco, California-based VIR Biotechnology is engaged in treating and preventing infectious diseases.  On December 7, VIR and GlaxoSmithKline plc (GSK) announced an update to preclinical data on their investigational monoclonal antibody, Sotrovimab. The antibody is authorized for treatment of early COVID-19 in the US.

For the previous nine months ended September 30, 2021, VIR posted revenue of US$282.7 million and net income of US$3.33 million. The revenue and net loss in the corresponding period in 2020 were US$74.6 million and US$193 million.

The company has a market capitalization of US$5.8 billion. Its forward P/E for one year is 38.25. The stock closed at US$43.6 on December 10. 

Also Read: Are these 7 utility stocks poised for another year of growth?     

GlaxoSmithKline PLC (NYSE: GSK)

Brentford, U.K.-based GSK is one of the largest companies in the pharmaceuticals industry in the world.

For the nine months ended June 30, 2021, the turnover was US$33.97 billion, and the operating profit was US$7.33 billion.  

The company has a market capitalization of US$108.6 billion. Its P/E ratio is 18.29, and forward P/E for one year is 14.03. Its dividend yield is 4.84%. The stock closed at US$43.17 on December 10, 2021. 

Also Read: 1inch, P4 eye Dec 13 debut of NFT collection on Binance– Know price

Johnson & Johnson (NYSE: JNJ)

Brunswick, New Jersey-based Johnson & Johnson, is one of the most diverse healthcare companies in the world. For the nine months ended October 3, 2021, the company booked sales of US$68.97 billion compared to US$60.1 billion for the previous year’s nine months. Net earnings for the period in 2021 were US$16.14 billion versus US$12.98 billion in the corresponding period in 2020.

On December 9, the company announced that the Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) had given approval for the use of the Johnson & Johnson COVID-19 vaccine to be used as a booster in people of 18 years and older.

The company has a market capitalization of US$435.6 billion. Its P/E ratio is 24.74, and forward P/E for one year is 16.96. The stock closed at US$165.49 on December 10. Its dividend yield is 2.5%. 

Also Read: Five hot healthcare stocks to watch as Omicron threat looms

 

 (TOP 8 vaccine stock of 2021)

Source - pixabay

Merck & Company, Inc. Common Stock (new) (NYSE: MRK)

Kenilworth, New Jersey-based Merck is a pharmaceutical company engaged in making products for cancer, infections, and cardiometabolic diseases. On November 30, the company informed about the positive vote from the Antimicrobial Drugs Advisory Committee (AMDAC) of the U.S. Food and Drug Administration’s (FDA) for emergency use authorization (EUA) application of molnupiravir, its investigational oral antiviral medicine to be used for mild to moderate COVID-19 patients who are at high risk of severe COVID-19. 

For the nine months ended September 30, 2021, Merck’s sales were US$35.18 billion, and net income was US$9.29 billion. The sales and net income were US$30.5 billion and US$9.16 billion, respectively, for the nine months ended September 30, 2020.

The company has a market capitalization of US$183 billion. Its P/E ratio is 25.66, and forward P/E for one year is 12.56. Its dividend yield is 3.55%. The stock closed at US$72.62 on December 10. 

Bottom line:

The healthcare sector is uncertain, and there are many levels of clearance required for vaccines or other drugs. So, investors have to select a stock after due analysis and with care.

Disclaimer

Speak your Mind

Featured Articles